TOPLINE: In patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (ERBB2)–negative metastatic breast cancer who progressed following endocrine plus cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy, longer duration of CDK4/6 inhibitor therapy was associated with improved overall survival, while the presence of visceral metastases was associated with worse overall survival. Following […]
The post Factors Linked to Survival Outcomes in Mets Breast Cancer first appeared on News Health.
Author : News Health
Publish date : 2025-03-10 12:14:00
Copyright for syndicated content belongs to the linked Source.